Progression-free and overall survival data from Companion-002 are due this quarter.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.
The anti-PD-1 x CTLA-4 bispecific impresses in cervical cancer, but US plans are on ice.
The company talks up Rybrevant plus Lazcluze’s disease-modifying potential, but still has much to prove.
Skyscraper-01 stars at AACR's upcoming clinical trial plenary.
The company is abandoning ovarian and bladder, but still sees a path in endometrial cancer.
The Artistry-7 Keytruda combo trial fails, spurring discontinuation in ovarian cancer.
